Article

Impact of Daratumumab in Transplant Eligible/Ineligible Patients with Newly Diagnosed Multiple Myeloma: An Updated Meta-Analysis of Phase- III Trials

2024-09-24

Abstract excerpt

<h4>Background: </h4> and Objectives: Daratumumab, a monoclonal antibody against CD38, has shown promising results in multiple myeloma (MM). We aimed to analyze its efficacy in newly diagnosed patients with MM. <h4>Materials and Methods:</h4> A search was conducted in PubMed, Cochrane, and Clinicaltrials.gov using the MeSH terms “daratumumab” or “Darzalex” and “multiple myeloma” covering the period until 2024. The...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 1c72cd9b-c9e8-59ac-bd62-40a62d0ee81e
DOI: 10.20944/preprints202409.1922.v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Impact of Daratumumab in Transplant Eligible/Ineligible Patients with Newly Diagnosed Multiple Myeloma: An Updated Meta-Analysis of Phase- III TrialsDOI 10.20944/preprints202409.1922.v1Read

Pattern of Use and Efficacy of Daratumumab-based Therapy in Patients With Multiple Myeloma in a Real-world Setting: a Single Institution ExperienceSemantic proximity Read

Real-world results of autologous stem cell transplantation in newly diagnosed multiple myeloma: a report from the Canadian Myeloma Research Group databaseSemantic proximity Read

Real-World Treatment Patterns and Clinical Outcomes in Patients With Multiple Myeloma Previously Treated With Lenalidomide and an Anti-CD38 Monoclonal AntibodySemantic proximity Read

Outcomes of CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma by Race: A Multicenter Real-World StudySemantic proximity Read

Targeting CD38 with Daratumumab Monotherapy in Multiple MyelomaSemantic proximity Read

Matching-adjusted indirect comparison of isatuximab plus carfilzomib and dexamethasone with daratumumab plus lenalidomide and dexamethasone in relapsed multiple myelomaSemantic proximity Read

Potential role of daratumumab in the treatment of multiple myelomaSemantic proximity Read

Perspectives on Drug Development in Multiple Myeloma-Looking Forward to 2025.Semantic proximity Read

Treatment outcome of newly diagnosed multiple myeloma patients: A retrospective analysis in a resource-limited settingSemantic proximity Read

Establishing Measurable Residual Disease Trajectories for Patients on Treatment for Newly Diagnosed Multiple Myeloma as Benchmark for Deployment of T-cell Redirection TherapySemantic proximity Read

Second Primary Malignancies Post Autologous Stem-cell Transplant in Multiple Myeloma from India – Knowing the UnknownSemantic proximity Read

T-Cell Characteristics Impact Response and Resistance to T-Cell–Redirecting Bispecific Antibodies in Multiple MyelomaSemantic proximity Read